Prosecution Insights
Prosecution Insights
21 pending office actions • 17 clients • 21 examiners • 16 art units • 0 of 21 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 4 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 4 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 4 (19%) |
| §103 only | 2 (10%) |
| §112 only | 2 (10%) |
| Double-patenting only | 1 (5%) |
| Double-patenting + other | 1 (5%) |
| Multi-statute (no §101) | 10 (48%) |
| No statute on record | 1 (5%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERRIN, CLARE M | 1 | 68.0% | +42.0% |
| ALAM, AYAAN A | 1 | 37.2% | +34.5% |
| MOU, LIYUAN | 1 | 43.5% | +57.7% |
| ROBINSON, HOPE A | 1 | 67.7% | +43.6% |
| O DELL, DAVID K | 1 | 57.7% | +36.0% |
| CHERNYSHEV, OLGA N | 1 | 54.5% | +34.2% |
| ALSOMAIRY, SARAH ABDOALATIF | 1 | 59.4% | +26.5% |
| KOLB, KATARZYNA I | 1 | 44.4% | +16.4% |
| MCMILLIAN, KARA RENITA | 1 | 30.4% | +37.9% |
| RODRIGUEZ-GARCIA, VALERIE | 1 | 68.8% | +31.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18278639 | CO-EXPRESSED CXCR2 AND T CELLS OF STAR SPECIFIC TO GPC3, AND USE THEREOF | LEE, YIE CHIA | 22d overdue |
| 18283385 | MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING | JOHNSON, TIRONE DEREK | 34d |
| 18722120 | ANTIMICROBIAL SYSTEM AND METHOD | PERRIN, CLARE M | — |
| 18695839 | RUXOLITINIB COMPOSITION AND PREPARATION METHOD THEREFOR | ALAM, AYAAN A | — |
| 18684205 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | MOU, LIYUAN | — |
| 18534843 | ARGININE WASH IN PROTEIN PURIFICATION | ROBINSON, HOPE A | — |
| 18561909 | Compound containing phosphate group, pharmaceutical composition containing same, preparation method therefor and use thereof | O DELL, DAVID K | — |
| 18290553 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | ALSOMAIRY, SARAH ABDOALATIF | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 8 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18283834 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | RODRIGUEZ-GARCIA, VALERIE | 60d |
| 18722120 | ANTIMICROBIAL SYSTEM AND METHOD | PERRIN, CLARE M | — |
| 18695839 | RUXOLITINIB COMPOSITION AND PREPARATION METHOD THEREFOR | ALAM, AYAAN A | — |
| 18684205 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | MOU, LIYUAN | — |
| 18534843 | ARGININE WASH IN PROTEIN PURIFICATION | ROBINSON, HOPE A | — |
| 18561909 | Compound containing phosphate group, pharmaceutical composition containing same, preparation method therefor and use thereof | O DELL, DAVID K | — |
| 18511241 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | CHERNYSHEV, OLGA N | — |
| 18290553 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | ALSOMAIRY, SARAH ABDOALATIF | — |
| Art Unit | Apps |
|---|---|
| 1675 | 3 |
| 1621 | 2 |
| 1611 | 1 |
| 1628 | 1 |
| 1646 | 1 |
| 1767 | 1 |
| 1623 | 1 |
| 1637 | 1 |
| 1642 | 1 |
| 1672 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18722120 | ANTIMICROBIAL SYSTEM AND METHOD | Kemira Oyj | PERRIN, CLARE M | §103§112 | Non-Final OA | — | Pending | Jun 20, 2024 | |
| 18695839 | RUXOLITINIB COMPOSITION AND PREPARATION METHOD THEREFOR | Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. | ALAM, AYAAN A | 1611 | §103§112 | Non-Final OA | — | Pending | Mar 27, 2024 |
| 18684205 | 1, 4-OXAZEPANE DERIVATIVES AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. | MOU, LIYUAN | 1628 | §103§112 | Non-Final OA | — | Pending | Feb 16, 2024 |
| 18534843 | ARGININE WASH IN PROTEIN PURIFICATION | H. Lundbeck A/S | ROBINSON, HOPE A | §103§112 | Non-Final OA | — | Pending | Dec 11, 2023 | |
| 18561909 | Compound containing phosphate group, pharmaceutical composition containing same, preparation method therefor and use thereof | Shanghai Raising Pharmaceutical Co., Ltd. | O DELL, DAVID K | 1621 | §101§102§103§112DP | Non-Final OA | — | Pending | Nov 17, 2023 |
| 18511241 | TREATMENT OF MEDICATION OVERUSE HEADACHE USING ANTI-CGRP OR ANTI-CGRP-R ANTIBODIES | H. Lundbeck A/S | CHERNYSHEV, OLGA N | 1675 | Other | Final Rejection | — | Pending | Nov 16, 2023 |
| 18290553 | METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANCIES | Precision Biologics, Inc. | ALSOMAIRY, SARAH ABDOALATIF | 1646 | §102§103§112 | Non-Final OA | — | Pending | Nov 14, 2023 |
| 18004579 | CYCLODEXTRIN DIMERS AND USES THEREOF | Cyclarity Therapeutics, Inc. | KOLB, KATARZYNA I | 1767 | §101§102§103§112Other | Non-Final OA | — | Pending | Oct 09, 2023 |
| 18284897 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. | MCMILLIAN, KARA RENITA | 1623 | §112 | Non-Final OA | — | Pending | Sep 29, 2023 |
| 18283834 | NOVEL COMPOUNDS USEFUL AS STING AGONISTS AND USES THEREOF | Jacobio Pharmaceuticals Co., Ltd. | RODRIGUEZ-GARCIA, VALERIE | 1621 | §112 | Non-Final OA | 60d | Pending | Sep 25, 2023 |
| 18283385 | MULTISPECIFIC PROTEINS COMPRISING AN NKP46-BINDING SITE, A CANCER ANTGIENGE BINDING SITE FUSED TO A CYTOKINE FOR NK CELL ENGAGING | Innate Pharma | JOHNSON, TIRONE DEREK | 1675 | §103§112 | Non-Final OA | 34d | Pending | Sep 21, 2023 |
| 18282711 | GUIDE RNAS AND COMPOSITIONS FOR EDITING HUNTINGTIN GENE, AND METHODS RELATED THERETO | Incisive Genetics, Inc. | TATGE, LEXUS MARC | 1637 | §102§112 | Non-Final OA | — | Pending | Sep 18, 2023 |
| 18278639 | CO-EXPRESSED CXCR2 AND T CELLS OF STAR SPECIFIC TO GPC3, AND USE THEREOF | (Shanghai Icell Biotechnology Co., Ltd.) | LEE, YIE CHIA | 1642 | §103§112 | Non-Final OA | 22d overdue | Pending | Sep 06, 2023 |
| 18150917 | METHOD FOR IDENTIFYING AND/OR REGULATING SENESCENCE | Institute Of Zoology, Chinese Academy Of Sciences | JADHAO, SAMADHAN JAISING | 1672 | DP | Non-Final OA | — | Pending | Aug 03, 2023 |
| 18271106 | NOVEL STEROID PAYLOADS, STEROID LINKERS, ADCs CONTAINING AND USE THEREOF | Immunext, Inc. | CHANDRAKUMAR, NIZAL S | 1625 | §103§112 | Non-Final OA | — | Pending | Jul 06, 2023 |
| 18148448 | WNT RECEPTOR-SPECIFIC COMPOUND AND METHOD RELATING THERETO | Surrozen Operating, Inc. | WANG, CHANG YU | 1675 | §102§112DPOther | Non-Final OA | 77d | Pending | Dec 30, 2022 |
| 18064514 | CHIMERIC ANTIGEN RECEPTORS TARGETING TIM-1 | Celldex Therapeurics, Inc. | SKELDING, ZACHARY S | 1644 | §102§103§112 | Non-Final OA | — | Pending | Dec 12, 2022 |
| 17923264 | DIRECTED EVOLUTION METHOD BASED ON PRIMARY AND SECONDARY REPLICON OF GEMINI VIRUS | Suzhou Qi Biodesign Biotechnology Company Limited | PARISI, JESSICA DANIELLE | 1684 | §101§102§103§112 | Final Rejection | — | Pending | Nov 04, 2022 |
| 17790206 | FTNIR SPECTROSCOPY FOR REACTION MONITORING OF ACRYLAMIDE SYNTHESIS | Kemira Oyj | KOROTCHKINA, LIOUBOV G | 1653 | §103 | Non-Final OA | — | Pending | Jun 30, 2022 |
| 17440299 | ANTI-ADAM12 ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS, AND COMPOSITIONS AND METHODS COMPRISING | Javelin Oncology, Inc. | WU, JULIE ZHEN QIN | 1600 | §101§102§103§112 | Non-Final OA | — | Pending | May 06, 2022 |
| 17637093 | POLYAMIDE 56 FIBRE WITH LOW BOILING WATER SHRINKAGE RATE, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF | Cibt America Inc. | PIZIALI, ANDREW T | 1789 | §103 | Final Rejection | — | Pending | Feb 22, 2022 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial